<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860729</url>
  </required_header>
  <id_info>
    <org_study_id>0859-022</org_study_id>
    <nct_id>NCT01860729</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)</brief_title>
  <official_title>A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of anacetrapib on low-density lipoprotein-cholesterol
      (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in participants with
      hypercholesterolemia when added to an existing statin therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Baseline in LDL-C (beta-quantification [BQ] method)</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change from Baseline in HDL-C</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Consecutive Elevations ≥3x Upper Limit of Normal (ULN)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Creatine Phosphokinase Elevations ≥10xULN with or without Muscle Symptoms</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Sodium, Chloride, or Bicarbonate Elevations &gt;ULN or Potassium Levels &lt;Lower Limit of Normal (LLN)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Pre-specified Adjudicated Cardiovascular Serious Adverse Events or Death from Any Cause</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Significant Increase in Blood Pressure</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in non-HDL-C</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Apolipoprotein B (Apo-B)</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Apolipoprotein A-I (Apo-A-I)</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Lipoprotein(a) (lp[a])</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in HDL-C Among Participants with Low HDL-C at LDL-C Goal</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">589</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Anacetrapib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg tablet, oral, once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching tablet to Anacetrapib 100 mg, oral, once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anacetrapib</intervention_name>
    <arm_group_label>Anacetrapib</arm_group_label>
    <other_name>MK-0859</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  If female, cannot be of reproductive potential

          -  Has been treated with an appropriate dose of statin for at least 6 weeks

          -  Coronary heart disease (CHD) or other atherosclerotic vascular disease with multiple
             risk factors (including diabetes, metabolic syndrome) and/or high LDL-C/low HDL-C, or
             needing to meet a specific LDL-C/HDL-C goal

        Exclusion Criteria:

          -  Previously participated in a study with a cholesteryl ester transfer protein (CETP)
             inhibitor

          -  Homozygous familial hypercholesterolemia

          -  Severe chronic heart failure

          -  Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary
             intervention (PCI), coronary artery by-pass graft (CABG), unstable angina, or stroke
             within 3 months

          -  Uncontrolled hypertension

          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoproteins

          -  Active or chronic hepatobiliary, hepatic, or gall bladder disease

          -  History of mental instability, drug/alcohol abuse within the past five years or major
             psychiatric illness inadequately controlled and unstable

          -  History of ileal bypass, gastric bypass, or other significant condition associated
             with malabsorption

          -  Human immunodeficiency virus (HIV) positive

          -  History of malignancy ≤5 years

          -  Donated blood products or has had phlebotomy of &gt;300 mL within 8 weeks or intends to
             donate 250 mL of blood products or receive blood products within the projected
             duration of the study

          -  Currently taking medications that are potent inhibitors or inducers of cytochrome P450
             3A4 (CYP3A) (including but not limited to cyclosporine, systemic itraconazole or
             ketoconazole, erythromycin, clarithromycin, or telithromycin, nefazodone, protease
             inhibitors, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St John's
             wort) or has discontinued treatment &lt;3 weeks prior

          -  Consumes more than 2 alcoholic drinks per day

          -  Currently participating or has participated in a study with an investigational
             compound or device within 3 months

          -  Receiving treatment with systemic corticosteroids or taking systemic anabolic agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anacetrapib</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

